Daiwa analyst Narumi Nakagiri downgraded AbbVie (ABBV) to Neutral from Outperform with an $180 price target Don't Miss our Black Friday Offers: Unlock your investing potential with TipRanks ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on December 3. Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on the ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

After hours: 7:59:57 pm GMT-5 ...

After hours: December 6 at 7:58:18 p.m. EST ...